Latest news with #microscopy
Yahoo
15 hours ago
- Health
- Yahoo
World's first sound-powered microscope sees 5x deeper into brain without altering cells
For decades, scientists have pushed the limits of microscopy to capture sharper and deeper views of the brain. Traditional light-based systems can map the cortex in detail but struggle to reach deeper regions like the hippocampus without losing resolution. The challenge is even greater when imaging molecular activity inside single cells, which is an essential step in understanding brain function and diseases. MIT scientists and engineers have now built a microscope that overcomes this barrier by combining ultrafast light pulses with sound detection. The system can image at depths more than five times greater than existing methods without using dyes, chemicals, or genetic modification. Researchers believe it could transform neuroscience research and surgical applications. Seeing deeper into the brain The study shows the system can detect NAD(P)H, a molecule linked to cell metabolism and neuronal activity, through dense brain samples. Tests included a 1.1 millimetre thick human stem cell-derived cerebral organoid and a 0.7 millimetre slice of mouse brain tissue. 'That's when we hit the glass on the other side,' said W. David Lee, the postdoctoral researcher who designed the system, explaining that the samples were not large enough to push the technology's true limits. The device uses a three-photon excitation method, firing ultrashort light bursts at triple the molecule's normal absorption wavelength. These longer wavelengths scatter less and penetrate deeper into tissue. Most of the absorbed energy creates a rapid, microscopic thermal expansion inside the cell, generating sound waves. A sensitive ultrasound microphone detects these waves, and software turns them into sharp images. This process is called three-photon photoacoustic imaging. Merging advanced imaging techniques The team combined three-photon excitation, photoacoustic detection, and label-free imaging into a platform they call 'Multiphoton-In and Acoustic-Out.' This setup allows precise molecular detection without altering the tissue. The system can also identify other molecules, such as GCaMP, a calcium indicator used to track neural activity. Additionally, 'third-harmonic generation' imaging maps cellular structures, giving structural and molecular detail in the same scan. Co-lead author Tatsuya Osaki from The Picower Institute said the aim was to combine advanced techniques into one efficient process. This capability could help study conditions where NAD(P)H levels change, including Alzheimer's disease, Rett syndrome, and seizures. Because it works without labels, it could also guide brain surgeries by mapping activity in real time. The next goal is to test the system in living animals. In this case, both the light source and microphone will need to be on the same side of the tissue instead of opposite sides. Lee expects the system could image up to 2 millimetres deep in live brains. 'In principle it should work,' he said. Lee's earlier work through Precision Healing Inc. showed that NAD(P)H imaging can guide wound treatment. Now, the same approach may prove valuable for neurosurgery and brain research. The project was funded by the National Institutes of Health, the Simon Center for the Social Brain, The Picower Institute, and other sources. The study is published in the journal Light: Science and Applications. Solve the daily Crossword
National Post
4 days ago
- National Post
Quartz Imaging Launches PCI-AM Version 9 Featuring Groundbreaking Template Matching for Automated Semiconductor Metrology
Article content VANCOUVER, British Columbia — Quartz Imaging Corporation, a global leader in microscopy and metrology software, is proud to announce the release of PCI-AM Version 9, the latest and most advanced edition of its powerful automated measurement solution. Building on a long history of innovation, this release introduces a game-changing capability: AI-driven template matching, setting a new benchmark for automation in microscope-based semiconductor metrology. Article content Reimagining Metrology Through Intelligent Template Matching Article content At the heart of PCI-AM Version 9 is its new template matching engine, which allows users to design templates using an intuitive graphical editor and to specify what measurements are desired. Once designed, the software uses machine learning to automatically identify, align, and measure all instances of the template feature within individual and batched microscope images—no manual intervention required. This dramatically reduces measurement time, improves repeatability, and ensures consistency among users. Article content PCI-AM Version 9 is engineered to meet the demanding requirements of today's semiconductor industry, where achieving nanometer-scale measurement accuracy is critical to process control and device validation. As semiconductor architectures evolve—featuring increasingly intricate, multi-layered, and non-uniform geometries —traditional measurement techniques struggle to keep pace. PCI-AM rises to the challenge with intelligent template matching that accommodates complex patterns and subtle structural variations, enabling reliable, automated measurements across even the most advanced node designs. Article content 'This is one of the most important software releases in our company's history. The new template matching technology in PCI-AM Version 9 isn't just a feature—it's a fundamental advancement for semiconductor metrology,' said Andrew Brown, President of Quartz Imaging Corporation. 'As device geometries become more complex and tolerances tighter than ever, labs need tools that are not only accurate but intelligent. PCI-AM V9 delivers exactly that— powerful automation that enables our customers to stay ahead in a rapidly evolving industry.' Article content More Than Just a Feature — A New Era of Automation Article content PCI-AM Version 9 is built on Quartz Imaging's robust PCI platform, delivering a full suite of image capture, annotation, processing, and reporting tools—now seamlessly integrated with next-generation automation. Article content Looking Ahead: Innovation Beyond the Lab Article content Quartz Imaging's commitment to innovation doesn't end with this release. The introduction of template matching in PCI-AM Version 9 signals a broader shift toward intelligent automation in metrology—one that empowers scientists and engineers to do more with less effort, in less time. Whether it's supporting next-generation chip design or accelerating breakthroughs in materials development, Quartz's solutions are engineered to scale with your ambitions. Article content Article content Article content Article content Article content Article content
Associated Press
24-06-2025
- Business
- Associated Press
Zomedica Announces Issuance of Additional Patent for its TRUVIEW(R) Microscope
Intellectual Property Portfolio grows to 221 Patents and 140 Trademarks ANN ARBOR, MI / ACCESS Newswire / June 24, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ('Zomedica' or the 'Company'), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the issuance of a new patent related to its TRUVIEW microscope and provided an update on the Company's current intellectual property portfolio. The U.S. Patent related to the TRUVIEW microscope, manufactured, sold and distributed by Zomedica, was U.S. Patent No. 12,299,917 B2 issued recently for the Methods and Systems for Slide Imaging Calibration. Bill Campbell, Zomedica's Vice President of Imaging Systems and inventor of the TRUVIEW microscope, stated, 'Securing this patent is a significant milestone that underscores our commitment to innovation in digital microscopy. This protection not only validates the uniqueness of our focusing system but also strengthens our position as a leader in imaging solutions. We are excited about the possibilities this opens for enhancing image quality and usability in clinical applications. With the addition of this recently issued patent, Zomedica's IP portfolio now includes 77 issued U.S. patents and 144 issued international patents as well as 33 registered U.S. trademarks and 107 registered foreign trademarks related to its therapeutic device and diagnostic products. Larry Heaton, Chief Executive Officer of Zomedica stated, 'We are pleased to add this patent protecting our innovative TRUVIEW device to our growing portfolio. The Zomedica Research & Development team has been actively expanding our intellectual property portfolio through ongoing development of our innovative products. This protection enables us to devote resources to investing in growing new markets for our unique products, knowing that Zomedica's highly differentiated proprietary products will remain unique.' About Zomedica Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $65 million in liquidity as of March 31, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit Follow Zomedica Cautionary Note Regarding Forward-Looking Statements Except for statements of historical fact, this news release contains certain 'forward-looking information' or 'forward-looking statements' (collectively, 'forward-looking information') within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as 'plan', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate' and other similar words, or statements that certain events or conditions 'may' or 'will' occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts. Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at Readers are cautioned that this list of risk factors should not be construed as exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information. Investor Relations Contact: Zomedica Investor Relations [email protected] 1-734-369-2555 SOURCE: Zomedica Corp. press release
Yahoo
06-05-2025
- Business
- Yahoo
New Inverted Light-Sheet Microscopy Platform for Research and Clinical Applications
"We are excited to collaborate with Alpenglow and leverage their deep expertise in AI and software development," said Dr. Michael Albiez, Head of ZEISS Research Microscopy Solutions. "This partnership combines Alpenglow's rapidly growing reputation with pharmaceutical companies and clinicians with the leadership of ZEISS in light-sheet microscopy, enabling the creation of powerful, fully integrated workflows for 3D pathology, from sample to analytics." "Partnering with ZEISS represents a significant step forward in our mission to revolutionize pathology by extracting and analysing the wealth of information contained in every single cell of a biopsy, rather than relying on just a small fraction of the tissue," said Dr. Nicholas Reder, CEO of Alpenglow Biosciences. "ZEISS's long-standing history of innovation in light-sheet microscopy is the perfect complement to our cutting-edge software and AI capabilities. Together, we will innovate and expand our existing 3D pathology platform that not only advances the needs of biopharma but also transforms clinical practice." By combining the industry-leading technologies of Alpenglow and ZEISS, the collaboration will enable the broader adoption of 3D pathology across research, translational and clinical applications. As part of the multi-phased collaboration, the companies will develop key applications in: Enhanced 3D pathology workflows (enabling microtome-free, direct digitization of entire tissue samples for improved 3D diagnostics and workflow efficiency), translational research (studying disease biology across 3D volumes enabling detection of immune cell infiltration patterns and characterization of novel biomarkers), drug development (understanding mechanisms of action and optimizing patient selection for clinical trial samples), AI-enabled clinical decision support (predicting treatment response and patient prognosis using AI-driven analysis of rich 3D imaging datasets). JENA, Germany & SEATTLE, May 06, 2025 --( BUSINESS WIRE )--ZEISS and Alpenglow Biosciences today announced a new partnership to jointly develop an inverted light-sheet microscope and bioinformatics pipeline tailored specifically for clinical applications. Alpenglow, a pioneering 3D spatial biology company specializing in open-top light-sheet microscopy, data processing, and AI-driven analysis for biopharma and clinical applications, has partnered with ZEISS, a global leader in light-sheet imaging technologies and visualization software – including ZEISS Lattice Lightsheet 7 and arivis software. Story Continues Dr. Albiez further emphasized, "At ZEISS, we are committed to driving innovation in imaging solutions that bridge the gap between research and clinical applications. This collaboration with Alpenglow marks a significant milestone in advancing workflows for clinical pathology. Together, we are introducing an integrated solution for analysing entire tissue samples and improving reproducibility to meet the evolving needs of both translational research and clinical settings. This collaboration will enable researchers and clinicians to gain deeper insights into tissue and cellular structures with greater efficiency and precision, ultimately facilitating more personalized and effective treatments." The partnership will create the fastest whole tissue imaging solution by combining exacting engineering and arivis visualization platform from ZEISS with Alpenglow's innovative data processing and AI capabilities. Once imaged, a GPU-accelerated imaging analytics pipeline could allow users to go from tissue to clinically impactful insights at the same time or faster than traditional pathology workflows. The generation of 3D images from entire tissues provides the perfect substrate for AI to make individualized treatment predictions for patients. Ultimately, these innovative technologies will deliver tools that streamline pathology workflows and enable earlier, more accurate clinical decision-making. About ZEISS ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue around 11 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (30 September 2024). For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars. With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future. With over 46,000 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, around 40 research and development facilities, and 35 production facilities worldwide (30 September 2024). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG. Further information at ZEISS Research Microscopy Solutions ZEISS Research Microscopy Solutions is the leading provider of light, electron, X-ray microscope systems, correlative microscopy and software solutions leveraging AI technologies. The portfolio comprises of products and services for life sciences, materials and industrial research, as well as education and clinical routine applications. The unit is headquartered in Jena. Additional production and development sites are located in Germany, UK, USA and China. ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment. Further information at About Alpenglow Biosciences Alpenglow Biosciences is a 3D spatial biology company focused on accelerating drug development and improving clinical diagnostics with AI-enabled 3D imaging technology. Their platform solution provides new spatial biology insights with greater accuracy by non-destructively digitizing entire tissues. Alpenglow partners with pharmaceutical companies to bring better therapeutics to market faster through greater understanding of mechanism of action, efficacy & toxicology, and clinical trial enrollment using their patented platform. See what you've been missing at View source version on Contacts Press contact ZEISS Research Microscopy Solutions Vybhav Sinha Phone: +49 3641 64 3949 Email: Alpenglow Biosciences Sarah Malik Phone: (206) 455-3170 Email: media@
